title: Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
authors.forename: M
authors.initials: M
authors.lastname: Senatore
authors.forename: G
authors.initials: G
authors.lastname: Coppolino
authors.forename: T
authors.initials: T
authors.lastname: Papalia
authors.forename: R
authors.initials: R
authors.lastname: Greco
authors.forename: D
authors.initials: D
authors.lastname: Lofaro
authors.forename: R
authors.initials: R
authors.lastname: Bonofiglio
mesh_terms: D000368:Aged; D002614:Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications*; D007811:Lanthanum / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood; D011073:Polyamines / Q000009:adverse effects* / Q000627:therapeutic use*; D006435:Renal Dialysis / Q000009:adverse effects; D000069603:Sevelamer
chemical_list: D002614:Chelating Agents; D010710:Phosphates; D011073:Polyamines; C119467:lanthanum carbonate; D007811:Lanthanum; D000069603:Sevelamer